GlassScriptPhysician profile
Abdulrahman Morad
NPI 1619288263
$4,060.79
in general payments reported to CMS, 2019-2025
22 companies · $2,002 in 2025
The $2,002 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $104 · 2021: $217 · 2022: $435 · 2023: $565 · 2024: $607 · 2025: $2,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,142 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,141.55 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,595.80 | 2025 | Rapiblyk |
| Amgen INC. | $858.29 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $227.45 | 2023-2024 | Ozempic, Wegovy, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $206.08 | 2021-2025 | Camzyos |
| Pfizer INC. | $152.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $148.47 | 2020-2025 | Farxiga, Andexxa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $144.83 | 2019-2024 | Lifevest |
| Medtronic, INC. | $144.71 | 2022 | |
| Merck Sharp & Dohme LLC | $100.79 | 2022-2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $88.95 | 2019-2024 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $76.49 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.80 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $45.92 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $44.66 | 2020-2024 | Xarelto |
| Amarin Pharma, INC. | $29.51 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.17 | 2019 | |
| Atricure, INC. | $23.05 | 2024 | |
| Philips North America LLC | $16.95 | 2024 | (Ao0) Igt Devices Intracardiac |
| Kiniksa Pharmaceuticals, LTD. | $16.82 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $16.46 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $15.73 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdulrahman Morad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.